Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

Advanced prostate cancer treatment requires a personalized approach, considering disease stage, comorbidities, and patient preferences. ARPIs have revolutionized treatment, highlighting the need for ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

If you’re dealing with advanced prostate cancer, the thought of surgery might feel like a lot to take in — and that’s completely understandable. For many men facing an advanced diagnosis, surgery will ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 prostate cancer-related deaths. As such, prostate cancer remains the most ...